ACTRN12614001022651已完成1 期
A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of DV-928 in Healthy Volunteers
INC Research0 个研究点目标入组 36 人开始时间: 2014年9月24日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 19 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Be in good health as determined by medical history, physical examination, 12 lead ECG and clinical laboratory evaluations at screening;
- •-Male subjects must agree to use a medically acceptable method of contraception/birth control throughout the study duration and for 90 days after the study is completed.
- •-Female subjects must be of non-childbearing potential
排除标准
- •-Significant blood loss or donated blood in the 30 days prior to study participation
- •-Participation in an investigational drug study within 30 days prior to dosing.
- •-History of drug or alcohol abuse.
- •-Use of any medications, including OTC and herbal or nutritional supplements during the week prior to drug dosing
- •-Positive tests for HIV, hepatitis B/C, drugs of abuse or alcohol breath-test.
- •-Clinically significant abnormalities
研究者
相似试验
已完成
1 期
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZ-3102 (single and multiple ascending doses) in Healthy Volunteersysosomal storage disordersLysosomal storage disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersMetabolic and Endocrine - Other metabolic disordersACTRN12621000576820Azafaros35
进行中（未招募）
1 期
Study of CHF6366 in healthy subjects and patients with Asthma and COPDEUCTR2015-005551-27-GBChiesi Farmaceutici106
已完成
不适用
A First-in-Human, randomized, double-blind, placebo-controlled ascending dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324 in healthy subjects.PainNL-OMON46459Stragen France78
招募中
1 期
A Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZE50 0134 in Healthy VolunteersChronic lymphocytic leukemia (CLL)Cancer - Leukaemia - Chronic leukaemiaACTRN12624000093583Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)40
招募中
不适用
CIT013 First in Human studyNL-OMON24009Citryll BV52